Takeda Pharmaceutical Announces FDA Approval of Colorectal Cancer Treatment
Pharmaceutical company Takeda JP:4502 announced Wednesday that the U.S. Food and Drug Administration has approved Fluzakura for the treatment of certain colorectal cancer patients. Fluzacra (fruquintinib), an oral targeted therapy, has been approved for adults with metastatic colorectal cancer who have received certain prior treatments. of…
Takeda receives FDA approval for fruquintinib for certain colorectal cancer patients
Photo: Takeda sign outside the California office/iStock; JHVE Photo The FDA on Wednesday approved Takeda Pharmaceutical’s fruquintinib for adult patients with previously treated metastatic colorectal cancer. Oral targeted therapy for VEGF-1, -2, and -3 receptors carries the brand name Furuzakura. Full Sakura-san label Patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan chemotherapy, and anti-VEGF agents are […]